Apr. 14 at 8:14 PM
Yesterday,
$NTRA highlighted positive interim results from the ALPHA3 trial involving Allogene Therapeutics, which uses Natera's Signatera MRD test to guide treatment in lymphoma patients.
Today, analysts at William Blair initiated coverage of Natera with an Outperform rating and no price target. Analyst Andrew Brackmann says the MRD testing market, estimated at more than
$20B, is still in early stages, with penetration currently in the mid- to high-single digits.
My husband has Lymphoma and Merkel Cell. He gets MRD/ctDNA testing every 3 months. The most recent tests were done through
$NTRA, but he has also had them done through
$TEM. Not a cheap test -
$3,000.
